These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31697814)

  • 1. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
    Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
    Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
    J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
    Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
    Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
    Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
    Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
    Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
    Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
    Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
    Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
    Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
    Ngu HS; Savage KJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
    Ngu HS; Savage KJ
    Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
    Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
    Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
    Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
    Sharman JP; Wheler JJ; Einhorn L; Dowlati A; Shapiro GI; Hilton J; Burke JM; Siddiqi T; Whiting N; Jalal SI
    Invest New Drugs; 2019 Aug; 37(4):738-747. PubMed ID: 30993587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
    Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
    Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.